Rocket Lab's $2.3 Billion Backlog Meets a Carbon-Composite Snag

Rocket Lab has no shortage of customers lining up. What it still lacks is a rocket big enough to carry them — and a manufacturing line that can build it cleanly. That tension sits at the heart of the investment case after the company pushed the maiden flight of its Neutron vehicle from late 2026 into 2027.

The delay traces back to a specific defect. After curing, inspectors found voids between the carbon-fiber layers in the forward dome of the first stage's fuel tank. This is a fabrication problem, not a demand problem, and the company has since reworked and tested its production process. CEO Peter Beck described a rear dome built under the revised method as the best quality the company has produced. Encouraging, yes — but it does not substitute for the inspections of the replacement forward dome that have yet to happen.

A Schedule Built on Completed Steps, Not Promises

Fabrication, curing and inspection of the new forward dome are slated for completion by the end of the year. Integration and qualification testing of the first stage are to follow in the first quarter of 2027. Only after those milestones will Rocket Lab name a more precise launch date.

That sequence is the more useful yardstick than hunting for the most optimistic launch month. Finished work steps say more about operational readiness than a fresh target date on its own.

The commercial stakes explain the scrutiny. Neutron is designed to carry roughly 13,000 kilograms of payload with a reusable first stage, and the company cites $50–55 million in revenue per launch. Behind the project sits not just another product but the prospect of a materially larger business per mission.

What the Order Book Actually Proves

The backlog stands at $2.3 billion, up 137% year over year, with about 45% expected to convert to revenue next year. That is a substantial demand cushion — but it is not evidence that every technical precondition for further growth has been met. A contract documents customer interest and creates commercial runway. A flight-ready rocket documents something different: the ability to actually deliver the service. Neither should be dismissed, and the two should not be confused.

Part of the larger business is a US Space Force award. Rocket Lab accounts for $397 million from a program to track aircraft and missile threats from space, and is to develop so-called Flatellites for large constellations, with Neutron launches planned. The contract ties satellite development to the future launch system — which is precisely why Neutron is more than an isolated engineering project.

The Street Trims Its Numbers but Keeps Its Ratings

Analysts have been recalibrating. Citizens cut its price target to $90 from $130 on Friday while keeping a positive rating, citing the Neutron delay's effect on monetizing later launches. KeyBanc had already lowered its target to $100 from $135 on Thursday, likewise maintaining a constructive stance. Cantor Fitzgerald's Andres Sheppard reaffirmed a buy rating with a $122 target.

The pattern across all three is the same: cooler numbers, unchanged conviction. Lower targets can express a more cautious view without abandoning the long-term picture — though they are a valuation of the future, not proof that the technical risks are behind the company. Nor does a lower target on its own establish that the difficulties will persist.

The Test Results Are the Real Catalyst

The pivotal question is whether the manufacturing fix holds up under scrutiny. Work on the process is not yet evidence that the voids are reliably avoided; only supporting test results can improve the basis for planning later launches with greater confidence. Citizens specifically flagged the monetization of those later launches as the pressure point, so a credible, evidence-backed schedule would matter more than a restated year.

In the favorable scenario, the corrections take hold and further tests underpin a new date. That would not recover the time already lost, but it could narrow the uncertainty around what comes next. Investors buying before meaningful test data accept the risk of prolonged ambiguity; those waiting for better confirmation may miss part of any positive move. No analyst target resolves that trade-off — only progress on the factory floor can.